Literature DB >> 17073251

Taxane-resistant lymphoepithelial-like carcinoma: excellent response to VIP chemotherapy.

A G Duffy1, G Wyse, A M Horgan, M O'Keefe, S O'Reilly, O S Breathnach.   

Abstract

BACKGROUND: Lymphoepithelial-like carcinoma is a rare tumour type. The optimal treatment for this disease is not known. No effective therapies are described in the literature. AIMS: This report describes a case of lymphoepithelial-like carcinoma and documents a therapeutic strategy which has proved effective.
RESULTS: The patient was initially treated with a common platinum-based chemotherapy regimen incorporating a taxane (Carbplatin and Docetaxel). Disease stabilization initially occurred but the patient soon progressed. The patient was then treated with VIP chemotherapy and had a complete response.
CONCLUSION: VIP chemotherapy appears to be an effective therapeutic strategy in lymphoepithelial-like carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073251     DOI: 10.1007/bf03169176

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  4 in total

1.  Lymphoepithelioma-like carcinoma of the skin with apparent origin in the epidermis--a pattern or an entity? A case report.

Authors:  A C Lind; W A Breer; M R Wick
Journal:  Cancer       Date:  1999-02-15       Impact factor: 6.860

2.  Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated "lymphoepithelioma-like" carcinoma as a distinct entity with better prognosis.

Authors:  F F Chen; J J Yan; W W Lai; Y T Jin; I J Su
Journal:  Cancer       Date:  1998-06-15       Impact factor: 6.860

3.  Lymphoepithelioma-like carcinoma of the uterine cervix: association with Epstein-Barr virus and human papillomavirus.

Authors:  C J Tseng; C C Pao; L H Tseng; C T Chang; C H Lai; Y K Soong; S Hsueh; H Jyu-Jen
Journal:  Cancer       Date:  1997-07-01       Impact factor: 6.860

Review 4.  The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas.

Authors:  J C Iezzoni; M J Gaffey; L M Weiss
Journal:  Am J Clin Pathol       Date:  1995-03       Impact factor: 2.493

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.